trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['breast']
what targeted therapies, specifically adcs, can do - practice changing results for her2-low (ihc 1+ or ihc 2+ /ish-) breast cancer, 45-55% of all breast cancers including subsets of er+ and tn bc. tdxd is better than chemo, improving pfs and os. #asco22 
Translational research scientist in Cancer Biotherapeutics, Molecular Therapeutics for Cancer, N.I.C.B.,Dublin City University https://t.co/mxY5z620Vu